Ratutrelvir is an investigational new drug that is being evaluated by Traws Pharma for the treatment of COVID-19 infections. It is a 3C-like protease inhibitor.
Clinical trials Ratutrelvir is currently in a phase 2 clinical trial to test the effectiveness and safety of the drug in patients with COVID-19 and a preliminary analysis of the results has been released.
References